Bionet

Bionet FCF Yield

The Free Cash Flow Yield of Bionet (1784.TWO) as of Nov 2, 2026 is 0.36 %. In the previous year, Free Cash Flow Yield was 1.64 % — a change of -78.28% (lower).

FCF Yield

0.36 %

YoY

-78.28%

Last updated:

Free Cash Flow Yield of Bionet is 2025 0.36 % . Free Cash Flow Yield of Bionet was 2024 1.64 % . It decreases by -78.28% lower compared to the previous year.

The Bionet FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-0.67 TWD
Jan 1, 2019
-0.20 TWD
Jan 1, 2020
0.80 TWD
Jan 1, 2021
-0.06 TWD
Jan 1, 2022
1.39 TWD
Jan 1, 2023
2.85 TWD
Jan 1, 2024
1.64 TWD
Jan 1, 2025
0.36 TWD
The Bionet FCF Yield history
YEARFCF YieldYoY
0.36 %-78.28%
1.64 %-42.43%
2.85 %+105.38%
1.39 %-2,315.43%
-0.06 %-107.82%
0.80 %-498.80%
-0.20 %-69.82%
-0.67 %-15.11%
-0.78 %-0.58%
-0.79 %-155.65%
1.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

Free Cash Flow Yield of Bionet is 0.36 % in 2025.

Free Cash Flow Yield of Bionet changed from 1.64 % to 0.36 %, representing a -78.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Bionet since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Bionet with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bionet

All Key Metrics — Bionet